Skip to content

Exploring the Use of Ibogaine in Opioid Recovery: Insights from Lived Experience

Jamie Walker, Daryle Deering, Bruno Hamish Unger

Journal of Psychoactive Drugs May 22, 2026 DOI: 10.1080/02791072.2026.2673843 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Qualitative collective case study Case report Peer reviewed
Sample size 10
Population Opioid-dependent individuals in New Zealand who used ibogaine for opioid detoxification
Intervention Ibogaine
Topics Addiction Ibogaine
Keywords Thematic analysis Context archaeology Opioid Psychosocial Nicotine Medical prescription Clinical psychology Psychotherapist Lived experience Euphoriant Qualitative research Chronic pain
Key findings Participants associated ibogaine treatment with rapid detoxification, improved mood, reduced anxiety, and periods of sustained abstinence, though relapse occurred in some cases.

Abstract

Opioid dependence is a public health concern in New Zealand, with limited treatment options beyond opioid substitution therapy (OST). Ibogaine, a psychoactive alkaloid with reported anti-withdrawal and anti-craving effects for opioid dependence, is legally available by prescription in New Zealand, offering a context for exploring user experiences. A qualitative collective case study design was used to examine the experiences and motivations of 10 opioid-dependent individuals who used ibogaine for opioid detoxification. Participants were recruited through ibogaine networks, OST services, and snowball sampling. Semi-structured interviews were conducted and analyzed using an inductive thematic analysis approach, informed by an interpretive, experiential framework. Analysis focused on how participants understood their motivations, treatment processes, safety practices, and post-treatment outcomes. Seven themes were identified: "Desperation to be opioid free," "motivations for using ibogaine," "safety conscious and support seeking," "improving ibogaine practices," "effects of treatment on depression and anxiety," "effects of treatment on dependence," and "the spiritual effect." Participants associated ibogaine treatment with rapid detoxification, improved mood, reduced anxiety, and periods of sustained abstinence, though relapse occurred in some cases. Preparation, medical screening, and post-treatment psychosocial support were critical to positive outcomes. This study adds to the literature by documenting experiences of ibogaine use, with implications for clinical practice, policy, and future research.

In the evidence

This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.

  • Participants associated ibogaine with rapid detoxification, improved mood, reduced anxiety, and periods of sustained abstinence, though relapse occurred in some cases.

    Synthesized

Comparable studies

Other case reports and case series on ibogaine for addiction, most cited first.

Study Year Design Participants
Long-QT Syndrome Induced by the Antiaddiction Drug Ibogaine A 31-year-old woman 2009 Case study n = 1
A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder. 31-year-old male military veteran with moderate alcohol use disorder 2018 Case study n = 1
Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report. 37-year-old female with severe opioid use disorder 2016 Case study n = 1
Ibogaine Consumption With Seizure-Like Episodes, QTc-Prolongation, and Captured Cardiac Dysrhythmias. 34-year-old white woman with heroin and cocaine use disorder 2019 Case study n = 1
Novel treatment of opioid use disorder using ibogaine and iboga in two adults Individuals with opioid use disorder accessing ibogaine through private unregulated... 2020 Case series n = 2

Explore topics

By condition and practice